A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma

Tian-En Li,Ze Zhang,Yi Wang,Da Xu,Jian Dong,Ying Zhu,Zheng Wang
DOI: https://doi.org/10.7150/jca.54408
IF: 3.9
2021-01-01
Journal of Cancer
Abstract:<p><b>Background and Aims</b>: The tumor microenvironment can be divided into inflamed, immune-excluded and immune<b>-</b>desert phenotypes according to CD8<sup>+</sup> T cell categories with differential programmed cell death protein 1 (PD-L1) expression. The study aims to construct a novel immunotype-based risk stratification model to predict postsurgical survival and adjuvant trans-arterial chemoembolization (TACE) response in patients with hepatocellular carcinoma (HCC).</p><p><b>Methods:</b> A total of 220 eligible HCC patients participated in this study. CD8<b><sup>+</sup></b> T cell infiltration and PD-L1 expression mode were estimated by immunohistochemical staining. A risk stratification model was developed and virtualized by a nomogram that integrated these independent prognostic factors. The postoperative prognosis and adjuvant TACE benefits were evaluated with a novel immunotype-based risk stratification model.</p><p><b>Results:</b> A total of 220 patients were finally identified. Immune-desert, immune-excluded, and inflamed immunotypes represented 45%, 24%, and 31% of HCC, respectively. Univariate and multivariate analyses identified immunotype and PD-L1 expression mode as independent prognostic factors for overall survival time (OS) and recurrence-free survival time (RFS). The nomogram was constructed by integrating immunotype, PD-L1 expression, Barcelona Clinic Liver Cancer (BCLC) stage and tumor grade. The C-index was 0.794 in the training cohort and 0.813 in the validation cohort. A risk stratification system was constructed based on the nomogram classifying HCC patients into 3 risk groups. The average OS times in the low-risk, intermediate-risk and high-risk groups in all cohorts were 77.1 months (95% CI 71.4-82.9), 53.7 months (95% CI 48.2-59.2), and 25.6 months (95% CI 21.4-29.7), respectively. Further analysis showed that OS was significantly improved by adjuvant TACE in the low- and intermediate-risk groups (<i>P=</i>0.041 and <i>P</i>=0.010, respectively) but not in the high-risk group (<i>P</i>=0.398).</p><p><b>Conclusion:</b> A novel immunotype-based risk stratification model was built to predict postoperative prognosis and adjuvant TACE benefit in HCC patients. These tools can assist in building a more customized method of HCC treatment.</p>
oncology
What problem does this paper attempt to address?